Antimicrobial resistance

R&D and investment

Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions

Research and development of new antimicrobial medicines, diagnostic tools, and vaccines must be reinvigorated.

The global community must encourage sustainable investments in new medicines, diagnostic tools, vaccines, and alternative interventions. The majority of pharmaceutical companies are no longer researching a new antibiotic which is a global concern for human and animal health. Research and development is needed to produce new treatments that can be deployed against multi-drug resistant infections.

To stimulate the development and production of affordable, equitable access to new medicines, diagnostic tools, vaccines, and alternatives, these medications may need to be de-linked from price and sales volume.

Pipeline analysis

WHO undertakes an annual review of antibacterial agents in the clinical development pipeline. The first report launched in September 2017 showed that the current pipeline is insufficient to treat the WHO priority pathogens, TB and C. difficile

Other Supporting Documents and Initiatives